menu
    • menu

    Company profile for SN BioScience

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SN BioScience provides nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA), peptide and protein to deliver in the form of nano-micelle, nanoparticle or liposome. The company's "double core-shell technology" and pool of acceptable lipids and polymers helps with difficulties in solubility or delivery. SN BioScience was founded in 2017 and is based in Seoul, South Korea.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SN BioSciencekorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    #307-2, 105 Bldg(East), Seoul National Univ Gwanak-ro 1, Gwanak-gu Seoul, 088...
    Telephone
    Telephone
    +82-32-818-9925
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.snbioscience.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SNB-101 Gets Government Support as Small Cell Lung Cancer Therapy
    SNB-101 Gets Government Support as Small Cell Lung Cancer Therapy

    16 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/snb-101-earns-government-backing-as-promising-therapy-for-small-cell-lung-cancer-302506245.html

    PR NEWSWIRE
    16 Jul 2025
    Share Share
    SN Bio Propels SNB-101 to Phase 2 with IND Clearance from FDA
    SN Bio Propels SNB-101 to Phase 2 with IND Clearance from FDA

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sn-bioscience-propels-snb-101-to-phase-2-with-ind-clearance-from-fda-302347791.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    EMA Grants SN Bio's SNB-101 Orphan Drug Status For SCLC
    EMA Grants SN Bio's SNB-101 Orphan Drug Status For SCLC

    31 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/following-the-fda-ema-also-grants-an-orphan-drug-designation-of-sn-biosciences-nano-anti-cancer-drug-snb-101-for-small-cell-lung-cancer-302160477.html

    PR NEWSWIRE
    31 May 2024
    Share Share
    SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
    SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

    09 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sn-bioscience-receives-fda-fast-track-designation-for-small-cell-lung-cancer-302142057.html

    PR NEWSWIRE
    09 May 2024
    Share Share
    SN Bio received FDA Orphan Drug Designation for Nano Anti-Cancer Drug 'SNB-101'
    SN Bio received FDA Orphan Drug Designation for Nano Anti-Cancer Drug 'SNB-101'

    29 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sn-bioscience-received-us-fda-orphan-drug-designation-for-its-nano-anti-cancer-drug-snb-101-on-pancreatic-cancer-302075576.html

    PR NEWSWIRE
    29 Feb 2024
    Share Share
    SN BioScience and Boryung Announce the Agreement on Generic Version of Abraxane
    SN BioScience and Boryung Announce the Agreement on Generic Version of Abraxane

    26 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sn-bioscience-and-boryung-announce-the-licensing-agreement-on-generic-version-of-abraxane-301731256.html

    PR NEWSWIRE
    26 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search